Actionable news
All posts from Actionable news
Actionable news in CELG: Celgene Corporation,

Celgene quarterly sales misses on soft demand for psoriasis drug

* Psoriasis drug Otezla Q1 sales of $242 mln

* Shares fall 3.1 pct to $121.30 premarket

* Q1 total revenue $2.96 bln vs est $3.03 bln (Adds details, analyst comment shares)

April 27 (Reuters) - U.S. biotechnology company Celgene Corp reported lower-than-expected sales, hurt in part by soft demand for its psoriasis treatment even as sales of its flagship drug Revlimid beat estimates.

Celgene's shares fell 3.1 percent to $121.30 in premarket trading on Thursday.

The company's cancer treatment Abraxane generated sales of $236 million and its...